Procaps Group Sa Stock Today
| PROC Stock | USD 2.09 0.73 53.68% |
Performance5 of 100
| Odds Of DistressLess than 45
|
Procaps Group is trading at 2.09 as of the 28th of November 2024, a 53.68% up since the beginning of the trading day. The stock's open price was 1.36. Procaps Group has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Procaps Group SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of September 2021 | Category Healthcare | Classification Health Care |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company was founded in 1977 and is based in Luxembourg, Luxembourg. Procaps Group is traded on NASDAQ Exchange in the United States. The company has 112.82 M outstanding shares of which 20.49 K shares are at this time shorted by private and institutional investors with about 1.65 trading days to cover. More on Procaps Group SA
Moving together with Procaps Stock
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.72 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Procaps Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Procaps Stock Highlights
| Founder Chairman | Ruben Minski | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProcaps Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Procaps Group's financial leverage. It provides some insight into what part of Procaps Group's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Procaps Group SA (PROC) is traded on NASDAQ Exchange in USA. It is located in 9 Rue de Bitbourg, Luxembourg, Luxembourg, 1273 and employs 5,500 people. Procaps Group is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 153.44 M. Procaps Group SA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 112.82 M outstanding shares of which 20.49 K shares are at this time shorted by private and institutional investors with about 1.65 trading days to cover.
Procaps Group SA currently holds about 37.55 M in cash with 62.99 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Procaps Group Probability Of Bankruptcy
Ownership AllocationProcaps Group owns a total of 112.82 Million outstanding shares. Procaps Group holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 83.02 pct. of Procaps Group SA outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Procaps Ownership Details
Procaps Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Exome Asset Management Llc | 2024-06-30 | 126.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 28.9 K | |
| State Street Corp | 2024-06-30 | 12.4 K | |
| Activest Wealth Management | 2024-06-30 | 10 K | |
| Royal Bank Of Canada | 2024-06-30 | 491 | |
| Pineridge Advisors Llc | 2024-09-30 | 250 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 200 | |
| Renaissance Technologies Corp | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 |
Procaps Group Historical Income Statement
Procaps Stock Against Markets
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procaps Group SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Earnings Share 0.51 | Revenue Per Share 4.097 | Quarterly Revenue Growth 0.073 | Return On Assets 0.0628 |
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.